SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

Share Price is delayed by 15 minutes
Get Live Data
2.21    0.00 (0.00%)
Bid:
2.19
Ask:
2.21
Spread: 0.02 (0.913%)
Market Cap: $714.60m
RTW Live PriceLast checked at - London Stock Exchange

Intraday Rtw Biotech Share Chart

Director Declaration

3 Oct 2023 16:00

RNS Number : 5644O
RTW Biotech Opportunities Ltd
03 October 2023
 

LEI: 549300Q7EXQQH6KF7Z84

03 October 2023

RTW Biotech Opportunities Ltd (the "Company")

Director Declaration

In accordance with Listing Rule 9.6.14(2), the Company advises that Paul Le Page, a non-executive director of the Company, has been appointed as an independent non-executive director of NextEnergy Solar Fund Limited, a LSE listed FTSE 250 company, with effect from 03 October 2023. In addition, Paul Le Page has recently resigned from Bluefield Solar Investment Fund Limited, an LSE listed FTSE 250 company.

Paul's role at NextEnergy Solar Fund Limited is not expected to impact his ability to allocate sufficient time to the Company to discharge his responsibilities effectively.

For Further Information:

RTW Investments, LP

+44 20 7959 6361

Woody Stileman, Managing Director

Krisha McCune, Director, Client Service

 

 

 

Buchanan

+44 20 7466 5107

Charles Ryland

 

Henry Wilson

 

George Beale

 

 

 

Numis

+44 20 7260 1000

Freddie Barnfield

 

Nathan Brown

 

Euan Brown

 

 

BofA Securities

+44 20 7628 1000

Edward Peel

 

Kieran Millar

 

 

Cadarn Capital

+44 73 6888 3211

David Harris

 

 

Elysium Fund Management Limited

Joanna Duquemin Nicolle, Chief Executive Officer

Sadie Morrison, Managing Director

+44 (0) 14 8181 0100

 

 

Morgan Stanley Fund Services USA LLC

+1 914 225 8885

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNBXBDGGSGDGXX
Date   Source Headline
30th Apr 20257:00 amRNSJade Biosciences merges with Aerovate Therapeutics
29th Apr 20257:00 amRNSTransaction in Own Shares
28th Apr 20257:00 amRNSTransaction in Own Shares
25th Apr 20257:00 amRNSTransaction in Own Shares
22nd Apr 20257:00 amRNSTransaction in Own Shares
17th Apr 20251:30 pmRNSAnnual Financial Report
16th Apr 20257:00 amRNSTransaction in Own Shares
14th Apr 20257:01 amRNSTransaction in Own Shares
14th Apr 20257:00 amRNSMonthly Valuation Update and Factsheet
10th Apr 202512:30 pmRNSDirector/PDMR Shareholding
10th Apr 20257:00 amRNSTransaction in Own Shares
9th Apr 20257:00 amRNSTransaction in Own Shares
7th Apr 20257:00 amRNSTransaction in Own Shares
3rd Apr 202512:30 pmRNSNew Investment in AIRNA
2nd Apr 20257:00 amRNSTransaction in Own Shares
1st Apr 20257:00 amRNSTotal Voting Rights
31st Mar 20257:00 amRNSAnnual Financial Report
28th Mar 20257:00 amRNSTransaction in Own Shares
26th Mar 20257:00 amRNSTransaction in Own Shares
21st Mar 20257:00 amRNSTransaction in Own Shares
20th Mar 20257:00 amRNSTransaction in Own Shares
14th Mar 20257:01 amRNSTransaction in Own Shares
14th Mar 20257:00 amRNSMonthly Valuation Update and Factsheet
13th Mar 20257:00 amRNSTransaction in Own Shares
10th Mar 20257:00 amRNSNotice of Annual Results
7th Mar 20257:00 amRNSTransaction in Own Shares
26th Feb 20257:00 amRNSRTW CIO increases position to 15%
25th Feb 20251:00 pmRNSMaterial purchase by CIO of the Investment Manager
17th Feb 20257:00 amRNSDirector/PDMR Shareholding
14th Feb 20257:00 amRNSMonthly Valuation Update and Factsheet
28th Jan 20257:00 amRNSMaterial Update from Portfolio Company
27th Jan 20257:00 amRNSKailera Reports Positive Data in Ph2 Obesity Trial
17th Jan 20257:01 amRNSNew Investment in Series A of Windward Bio
17th Jan 20257:00 amRNSAdditional Investment in Umoja Biopharma
15th Jan 20257:00 amRNSMonthly Valuation Update and Factsheet
14th Jan 20257:00 amRNSAdditional Investment in Numab Therapeutics
10th Jan 20257:00 amRNSNew Investment in Series A of Alesta Therapeutics
30th Dec 20247:00 amRNSCORXEL Announces Two Significant Transactions
20th Dec 202412:15 pmRNSNew Investment in Series A of Ottimo Pharma
13th Dec 20247:00 amRNSMonthly Valuation Update and Factsheet
10th Dec 202412:00 pmRNSHolding(s) in Company
10th Dec 20247:00 amRNSAppointment of Senior Independent Director
15th Nov 20247:00 amRNSCORXEL Announces Acceptance of NDA for Aficamten
14th Nov 20247:00 amRNSMonthly Valuation Update and Factsheet
1st Nov 20242:00 pmRNSNew Investment in Series C Round of Evommune, Inc.
1st Nov 20247:00 amRNSRTW Biotech Opportunities’ 5th Anniversary
14th Oct 20246:12 pmRNSMonthly Valuation Update and Factsheet Replacement
14th Oct 20247:00 amRNSMonthly Valuation Update and Factsheet
3rd Oct 20247:00 amRNSLaunch of Obesity Company Kailera Therapeutics
2nd Oct 20247:00 amRNSNew Investment in Aktis Oncology

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.